MyFinsight
Home
Blog
About
Contact
Download
Download image
Net proceeds from
issuance of common stock
$20,930,126
Issuance of note payable
$486,721
Net cash provided by
financing activities
$19,277,144
Effect of exchange rate
changes on cash and cash...
$7,186
Canceled cashflow
$2,139,703
Net change in cash,
cash equivalents and...
$9,013,182
Canceled cashflow
$10,271,148
Principal payments on
finance lease
$1,264,188
Payments on note payable
$553,829
Payments of deferred
offering costs
$321,686
Deferred grant funding
-$3,089,828
Depreciation and
amortization
$1,634,486
Stock-based compensation
expense
$1,496,562
Prepaid expenses
-$668,486
Interest payable
$572,561
Right-of-use asset -
operating lease
-$516,895
Non-cash interest
expense
$82,502
Net cash (used in)
provided by operating...
-$9,885,870
Net cash used in
investing activities
-$385,278
Canceled cashflow
$8,061,320
Interest income
$679,740
Other income
(expense), net
$296,029
Net loss
-$13,399,274
Purchases of property and
equipment
$385,278
Canceled cashflow
$975,769
Accrued expenses
-$2,250,627
Deferred revenue
-$1,000,000
Operating lease liability
-$548,638
Other receivables
$331,026
Accounts payable
-$255,146
Other non-current
assets
$78,723
Other current assets
$65,405
Accounts receivable
$12,053
Non-cash royalty revenue
related to sale of future...
-$6,298
Loss from operations
-$13,552,334
Interest expense
$822,709
Back
Back
Cash Flow
source: myfinsight.com
Dare Bioscience, Inc. (DARE)
Dare Bioscience, Inc. (DARE)